Fig. 4
From: A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan
Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of sacituzumab (anti-TROP2 antibody) or sacituzumab govitecan (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. ***p < 0.001.
